GlassScriptPhysician profile
Alex S Ro
NPI 1568559458
$8,783.61
in general payments reported to CMS, 2019-2025
19 companies · $716 in 2025
The $716 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,900 · 2020: $1,477 · 2021: $331 · 2022: $538 · 2023: $758 · 2024: $1,064 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,063 · Consulting Fee: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,062.55 |
| Consulting Fee | $475.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $5,200.00 | 2019-2020 | |
| Medtronic, INC. | $1,094.57 | 2021-2025 | Aurora Ev-Icd Mri Surescan, Micra, Pulseselect |
| Biosense Webster, INC. | $636.68 | 2021-2025 | Carto 3 |
| Abbott Laboratories | $339.10 | 2022-2023 | Ensite |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.40 | 2022-2024 | Jardiance |
| Pfizer INC. | $243.22 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $218.34 | 2025 | |
| Boston Scientific Corporation | $196.22 | 2022-2025 | Farapulse, General - Therapies |
| Medtronic Vascular, INC. | $177.28 | 2020 | |
| Janssen Pharmaceuticals, INC | $157.91 | 2021-2024 | Opsumit |
| E.R. Squibb & Sons, L.L.C. | $48.54 | 2023-2025 | Eliquis, Camzyos |
| Cordis US Corp. | $34.29 | 2024-2025 | Mynx Control, Mynx Control Venous |
| Elutia, INC. | $31.25 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $28.36 | 2025 | Onpattro |
| Chiesi USA, INC. | $24.74 | 2023 | Kengreal, Cleviprex |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.64 | 2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $18.42 | 2024 | |
| Cardiva Medical, INC. | $17.99 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Astrazeneca Pharmaceuticals LP | $13.66 | 2023 | Brilinta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Ro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.